YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Xvivo Perfusion AB (publ) press release [https://seekingalpha.com/pr/20486630-interim-report-january-march-2026] (XVIPF [https://seekingalpha.com/symbol/XVIPF]): Q1 GAAP EPS of SEK1.15. * Revenue of SEK241M. * Organic growth was 23 perce…
The latest tweak to fair value and what it signals The fair value estimate for Xvivo Perfusion has been trimmed slightly from SEK 319.6 to SEK 317.6, with a modestly higher discount rate and a small reduction in the revenue growth assumpti…
Xvivo Perfusion’s latest rating upgrade comes with a refreshed narrative rather than a fundamental shift in its intrinsic value, with the fair value estimate holding steady at SEK 319.6 while the formal price target moves higher. The modes…
As European markets navigate a landscape marked by persistent inflation pressures and geopolitical tensions, the pan-European STOXX Europe 600 Index has recently seen a decline of 1.54%. Amidst this backdrop, small-cap stocks present intri…
The European market has recently seen positive momentum, with the pan-European STOXX Europe 600 Index climbing 2.77% amid easing trade tensions and a more optimistic economic outlook. Despite some concerns about potential slowdowns in busi…
GOTHENBURG, SWEDEN / ACCESSWIRE / January 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Fourth quarter 2023 (October 1 - December 31) • Net sales amounted to SEK 155.7 million (131.5), corresponding to an increase of 18 perc…
GOTHENBURG, SE / ACCESSWIRE / January 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) In a recently published [1] clinical trial conducted by the UMCG in Groningen, the Netherlands, XVIVO's Liver Assist has demonstrated its p…
GOTHENBURG, SE / ACCESSWIRE / January 12, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Report on Operations 2023. The presentation will be held in E…
GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) In 2014, XVIVO introduced an innovative liver technology to the Italian market, designed for oxygenated perfusion prior to transplantat…
GOTHENBURG, SWEDEN / ACCESSWIRE / December 14, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) As communicated on July 12, 2023, XVIVO has decided to close its´ PrimECC study for further patient inclusions and to evaluate potentia…
GOTHENBURG, SE / ACCESSWIRE / November 3, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The results of the clinical trial conducted in Australia and New Zealand on XVIVO's heart technology were earlier this week published in the…
GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Third quarter 2023 (July 1 - September 30) • Net sales amounted to SEK 146.6 million (96.8), corresponding to an increase of 51 percent…
GOTHENBURG, SWEDEN / ACCESSWIRE / October 23, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) On October 14, 2023 Duke University Hospital in Durham, N.C., performed the first heart transplant in the U.S. using XVIVO's Non-Ischemi…
GOTHENBURG, SWEDEN / ACCESSWIRE / October 6, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report July-September 2023. The presentation will…
GOTHENBURG, SWEDEN / ACCESSWIRE / September 29, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The following members have been appointed to XVIVO Perfusion's nomination committee for the 2024 annual general meeting: Henrik Blomqu…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 25, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The US Food & Drug Administration (FDA) has approved XVIVO's Investigational Device Exemption (IDE) supplement for its heart preservation c…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 13, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) "Continued momentum for our business" Second quarter 2023 (Apr 1 - Jun 30) • Net sales amounted to SEK 154.6 million (94.3), corresponding…
GOTHENBURG, SE / ACCESSWIRE / July 12, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) PrimECC is a solution used to prime the heart-lung machine before heart-surgery. It is a CE-marked and patent-protected product and is develope…
GOTHENBURG, SE / ACCESSWIRE / July 10, 2023 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) A strategic collaboration agreement has been signed between XVIVO and MTJ Aviation, an American medical flight services company. The agreemen…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 3, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report April-June 2023. The presentation will be held…
GOTHENBURG, SE / ACCESSWIRE / June 21, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO acquired STAR Teams, an organ recovery service in the US, in November 2021. To meet the rapidly growing demand for recovery services in t…
GOTHENBURG, SE / ACCESSWIRE / May 23, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in a randomized controlled clinical trial across 15 leading transplant cent…
GOTHENBURG, SE / ACCESSWIRE / May 15, 2023 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) The US Food & Drug Administration (FDA) has approved XVIVO's Investigational Device Exemption (IDE) application for its´ heart preservation te…
GOTHENBURG, SE / ACCESSWIRE / May 11, 2023 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has, based on the authorisation given by the Annual General Meeting held on 25Ap…
GOTHENBURG, SE / ACCESSWIRE / April 25, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB (publ) ("XVIVO Perfusion" or the "Compan…
GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Record quarter for sales and gross margin First quarter 2023 (Jan 1 - Mar 31) • Net sales amounted to SEK 140.6 million (92.7), correspond…
GOTHENBURG, SWEDEN / ACCESSWIRE / April 17, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-March 2023. The presentation will be…
GOTHENBURG, SE / ACCESSWIRE / April 3, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2022. The Annual Report is attached to this press release in pdf format and in ES…
GOTHENBURG, SE / ACCESSWIRE / March 23, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL) (FRA:3XV) XVIVO Perfusion AB (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Gothenburg, gives notice of the the Annual Gen…
GOTHENBURG, SWEDEN / ACCESSWIRE / January 26, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Fourth quarter 2022 (October 1 - December 31) Net sales amounted to SEK 131.5 million (85.9), corresponding to an increase of 53 percent…
GOTHENBURG, SE / ACCESSWIRE / January 16, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Report on operations 2022. The presentation will be held in E…
GOTHENBURG, SE / ACCESSWIRE / December 30, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) As of today, 30 December 2022, the total number of shares and votes in XVIVO Perfusion AB (publ) is 29,831,919. The number of shares and vo…
GOTHENBURG, SWEDEN / ACCESSWIRE / November 30, 2022 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) The board of XVIVO Perfusion AB (publ) ("XVIVO") has appointed Christoffer Rosenblad as CEO. Christoffer has had the role of acting C…
GOTHENBURG, SE / ACCESSWIRE / November 30, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO Perfusion AB (publ) ("XVIVO") has today on November 30, 2022, completed the acquisition of all shares in XVIVO S.rl., acquired from X…
GOTHENBURG, SE / ACCESSWIRE / November 28, 2022 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) XVIVO continues to build and strengthen the company. XVIVO has a firm strategy plan for the coming five years, and as part of securing th…
GOTHENBURG, SE / ACCESSWIRE / November 24, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Earlier this month, Professor David Kaye of The Alfred in Melbourne, Australia, presented late breaking science at the American Heart Assoc…